{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:13:59Z","timestamp":1790702039062,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate urodynamic efficacy and safety of mirabegron add\u2010on treatment with tamsulosin for<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese male patients with overactive bladder (<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective study was conducted in 26 consecutive male patients with<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>who had been taking tamsulosin.<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>was diagnosed by overactive bladder symptom score (<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>). Before and 8\u2009weeks after mirabegron add\u2010on treatment with preceding tamsulosin, we assessed<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>nternational<jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>rostate<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>ymptom<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>core (<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>), free uroflowmetry (<jats:styled-content style=\"fixed-case\">UFM<\/jats:styled-content>), filling cystometry and pressure\u2010flow study (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age and prostate volume of the study patients were 75\u2009\u00b1\u20097\u2009years and 32\u2009\u00b1\u200919\u2009mL, respectively. Mirabegron significantly improved<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>(from 8.5\u2009\u00b1\u20092.3 to 4.7\u2009\u00b1\u20092.5,<jats:italic>P\u2009&lt;<\/jats:italic>\u20090.001). On free<jats:styled-content style=\"fixed-case\">UFM<\/jats:styled-content>, mirabegron significantly increased voided volume (from 135\u2009\u00b1\u200947 to 182\u2009\u00b1\u2009102\u2009mL,<jats:italic>P\u2009=<\/jats:italic>\u20090.01), maximum (from 10.7\u2009\u00b1\u20093.7 to 13.5\u2009\u00b1\u20096.4\u2009mL\/sec,<jats:italic>P\u2009&lt;<\/jats:italic>\u20090.01) and average flow rate (from 5.5\u2009\u00b1\u20091.9 to 7.1\u2009\u00b1\u20093.3\u2009mL\/sec,<jats:italic>P\u2009&lt;<\/jats:italic>\u20090.01), while postvoid residual urine volume did not change significantly (from 47\u2009\u00b1\u200938 to 63\u2009\u00b1\u200961\u2009mL,<jats:italic>P\u2009=<\/jats:italic>\u20090.23). Before mirabegron, 24 patients (92%) had detrusor overactivity (<jats:styled-content style=\"fixed-case\">DO<\/jats:styled-content>). After mirabegron add\u2010on, maximum cystometric capacity significantly increased from 170\u2009\u00b1\u200998 to 212\u2009\u00b1\u200995\u2009mL (<jats:italic>P\u2009=<\/jats:italic>\u20090.01) and<jats:styled-content style=\"fixed-case\">DO<\/jats:styled-content>disappeared in six patients (25%). In the other 18 patients with persistent<jats:styled-content style=\"fixed-case\">DO<\/jats:styled-content>, amplitude of involuntary contraction decreased and bladder volume at first involuntary contraction increased with statistical significance. On<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>, detrusor pressure at maximum flow rate (from 79\u2009\u00b1\u200931 to 68\u2009\u00b1\u200919\u2009cmH<jats:sub>2<\/jats:sub>O,<jats:italic>P\u2009=<\/jats:italic>\u20090.10) or bladder contractility index (from 126\u2009\u00b1\u200939 to 120\u2009\u00b1\u200927,<jats:italic>P\u2009=<\/jats:italic>\u20090.45) did not change significantly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mirabegron add\u2010on treatment with tamsulosin has efficacy and safety because it improves storage symptom without impairment of bladder contractility during voiding in male patients with<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12091","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T12:36:48Z","timestamp":1424176608000},"page":"171-176","source":"Crossref","is-referenced-by-count":28,"title":["Urodynamic Efficacy and Safety of Mirabegron Add\u2010on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder"],"prefix":"10.1111","volume":"8","author":[{"given":"Naoki","family":"WADA","sequence":"first","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"IUCHI","sequence":"additional","affiliation":[{"name":"Department of Urology Megumino Hospital Megumino Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"KITA","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"HASHIZUME","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"MATSUMOTO","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"KAKIZAKI","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.05.008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.02.055"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.003"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12649"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.062"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00494-3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(2000)19:2<113::AID-NAU2>3.0.CO;2-#"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02177.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00121.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for beta3\u2010adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda M","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702358"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.02.077"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.06.020"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)56550-7"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61994-3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.138651"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12091","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:18:41Z","timestamp":1747660721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/luts.12091"],"URL":"https:\/\/doi.org\/10.1111\/luts.12091","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,17]]}}}